358971-19-4Relevant academic research and scientific papers
Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
-
, (2008/06/13)
The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their us
Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions containing, as an active ingredient, at least one compound of formula: in which R1represents a radical —N(R4)R5, —N(R4)—CO—R5, —N(R4)—SO2R6or one of its pharmaceutically acceptable salts, to the novel derivatives of formula (I), to their pharmaceutically acceptable salts and to their preparation.
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
-
, (2008/06/13)
The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
